Healthcare Economist April 30, 2024
Jason Shafrin

In July 2018, FDA released the Biosimilars Action Plan (BAP), which outlined FDA’s approach for expanding access to biosimilars for the American public. The plan focused on 4 key areas:

A recent FDA report reviews some of their accomplishments since then. Most of these efforts revolve around guidance documents, additional staff, education products and websites, public hearings and regulations (i.e., proposed/final rules)....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech, Survey / Study, Trends
President-elect Trump's picks for CDC, FDA, surgeon general: 31 notes
Opinion: RFK Jr. and MAHA should champion a Marshall Plan for obesity
Trump picks Johns Hopkins surgeon to head FDA: 10 things to know
Regulatory Hurdles and Ethical Concerns Beset FDA Oversight of AI/ML Devices
Will Trump's healthcare appointments bring 'radical changes'?

Share This Article